SciBase Holding AB

Stockholm – September 17, 2026 -- SciBase Holding AB has pushed back the first day of trading in subscription rights and paid subscribed shares (BTA) tied to its ongoing rights issue by one day, moving the start date from September 15, 2026 to September 16, 2026 on Nasdaq First North Growth Market.

The subscription period itself remains unchanged, running from September 15 through September 29, 2026.

Timetable shift leaves subscription window intact

The Swedish medtech company confirmed the updated timetable applies only to the trading commencement of subscription rights and BTAs, not to the underlying subscription mechanics of the capital raise.

Michael Colérus, Chief Financial Officer of SciBase, is the designated contact for investor inquiries related to the adjustment.

Stockholm – September 11, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.

Collaboration targets relapse prediction in atopic dermatitis patients

SciBase and Castle Biosciences entered a collaboration and license agreement in 2025. The first joint study under that agreement aims to predict relapses in atopic dermatitis and is currently underway, with the new order funding both faster progression of that trial and groundwork for a follow-up study.